Ewing-like sarcomas with BCOR-CCNB3 fusion transcript: A clinical, radiological and pathological retrospective study from the Société Française des Cancers de L'Enfant

Pediatric Blood and Cancer

Volumn 61, Issue 12, 2014, Pages 2191-2198

  Cohen Gogo, Sarah ^a   Cellier, Cécile ^b   Coindre, Jean Michel ^c   Mosseri, Véronique ^b   Pierron, Gaëlle ^b   Guillemet, Cécile ^d   Italiano, Antoine ^c   Brugières, Laurence ^e   Orbach, Daniel ^b   Laurence, Valérie ^b   Delattre, Olivier ^a   Michon, Jean ^b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT BERGONIÉ   (France)

^d CENTRE HENRI BECQUEREL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adolescent; BCOR protein; Cyclin B3 protein; Ewing sarcoma; Fusion oncogene protein; Small cell sarcoma

Indexed keywords

BCOR PROTEIN, HUMAN; CCNB3 PROTEIN, HUMAN; CYCLIN B; ONCOPROTEIN; REPRESSOR PROTEIN;

ADOLESCENT; ADULT; BONE TUMOR; CANCER STAGING; CHILD; CLINICAL TRIAL; EWING SARCOMA; FEMALE; FOLLOW UP; FRANCE; GENE FUSION; GENETICS; HUMAN; LUNG TUMOR; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; CYCLIN B; FEMALE; FOLLOW-UP STUDIES; FRANCE; GENE FUSION; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; SARCOMA, EWING; SURVIVAL RATE; YOUNG ADULT;

EID: 84911478067     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25210     Document Type: Article

References (21)

1. Lessnick SL, Dei Tos AP, Sorensen PH, et al. Small round cell sarcomas. Semin Oncol 2009; 36:338-346.
2. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294-299.
3. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-165.
4. Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet 2012; 44:461-466.
5. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: Current management. Oncologist 2006; 11:503-519.
6. Gaspar N, Rey A, Berard PM, et al. Risk adapted chemotherapy for localised Ewing's sarcoma of bone: The French EW93 study. Eur J Cancer 2012; 48:1376-1385.
7. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47:22-29.
8. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A children's oncology group study. J Clin Oncol 2009; 27:2536-2541.
9. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694-701.
10. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the children's oncology group. J Clin Oncol 2012; 30:4148-4154.
11. Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011; 117:3027-3032.
12. Italiano A, Sung YS, Zhang L, et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 2012; 51:207-218.
13. Reinus WR, Gilula LA. Radiology of Ewing's sarcoma: Intergroup Ewing's Sarcoma Study (IESS). Radiographics 1984; 4:929-944.
14. Peersman B, Vanhoenacker FM, Heyman S, et al. Ewing's sarcoma: Imaging features. JBR-BTR 2007; 90:368-376.
15. Vade A, Eissenstadt R, Schaff HB. MRI of aggressive bone lesions of childhood. Magn Reson Imaging 1992; 10:89-96.
16. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's oncology group study D980. J Clin Oncol 2009 27:5182-5188.
17. Oberlin O, Le Deley MC, Dirksen U, et al. Randomized comparison of VAC versus VAI chemotherapy (CT) as consolidation for standard risk (SR) Ewing sarcoma tumor (ES): Results of the Euro-EWING 99-R1 trial. J Clin Oncol 2011; 29: abstr 9517.
18. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26:4385-4393.
19. Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 2010; 251:506-511.
20. Stoeckle E, Gardet H, Coindre JM, et al. Prospective evaluation of quality of surgery in soft tissue sarcoma. Eur J Surg Oncol 2006; 32:1242-1248.
21. Puls F, Niblett A, Marland G, et al. BCOR-CCNB3 (Ewing-like) Sarcoma: A clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma. Am J Surg Pathol 2014. [Epub ahead of print]